Track topics on Twitter Track topics that are important to you
The phase I/II CIRLL study, which is evaluating the combination of the monoclonal antibody cirmtuzumab (UC-961) plus ibrutinib has opened an expansion cohort to include patients with mantle cell lymphoma.
Original Article: Cirmtuzumab/Ibrutinib Study Expands to Include Patients With MCLNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...